Patent · US Active

C—glycolipids with enhanced Th-1 profile

US8883745B2 · kind B2 · utility

0Cited by

1References

22Claims

0Family size

Assignees

NEW YORK UNIVERSITY · US
The Aaron Diamond Aids Research Center For The City Of New York · US
RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK · US

Inventors

Moriya Tsuji · New York, US
Guangwu Chen · Beijing, CN
Richard Franck · Monroe, US
Guangli Yang · Elmont, US

Key dates

Filing date	May 22, 2007
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Sep 12, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.